Indigenous access to clinical services along the lung cancer treatment pathway: a review of current evidence.
Access
Disparities
Equity
Health care
Indigenous
Lung cancer
Survival
Treatment
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
16 Aug 2024
16 Aug 2024
Historique:
received:
24
04
2024
accepted:
06
08
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
aheadofprint
Résumé
Lung cancer is a deadly cancer. Early diagnosis and access to timely treatment are essential to maximizing the likelihood of survival. Indigenous peoples experience enduring disparities in lung cancer survival, and disparities in access to and through lung cancer services is one of the important drivers of these disparities. In this manuscript, we aimed to examine the current evidence on disparities in Indigenous access to services along the lung cancer treatment pathway. A narrative literature review was conducted for all manuscripts and reports published up until July 20, 2022, using Medline, Scopus, Embase, and Web of Science. Following the identification of eligible literature, full-text versions were scanned for relevance for inclusion in this review, and relevant information was extracted. After scanning 1,459 documents for inclusion, our final review included 36 manuscripts and reports that included information on lung cancer service access for Indigenous peoples relative to non-Indigenous peoples. These documents included data from Aotearoa New Zealand, Australia, Canada, and the USA (including Hawai'i). Our review found evidence of disparities in access to, and the journey through, lung cancer care for Indigenous peoples. Disparities were most obvious in access to early detection and surgery, with inconsistent evidence regarding other components of the pathway. These observations are made amid relatively scant data in a global sense, highlighting the need for improved data collection and monitoring of cancer care and outcomes for Indigenous peoples worldwide. Access to early detection and guideline-concordant treatment are essential to addressing enduring disparities in cancer survival experienced by Indigenous peoples globally.
Sections du résumé
BACKGROUND
BACKGROUND
Lung cancer is a deadly cancer. Early diagnosis and access to timely treatment are essential to maximizing the likelihood of survival. Indigenous peoples experience enduring disparities in lung cancer survival, and disparities in access to and through lung cancer services is one of the important drivers of these disparities. In this manuscript, we aimed to examine the current evidence on disparities in Indigenous access to services along the lung cancer treatment pathway.
METHODS
METHODS
A narrative literature review was conducted for all manuscripts and reports published up until July 20, 2022, using Medline, Scopus, Embase, and Web of Science. Following the identification of eligible literature, full-text versions were scanned for relevance for inclusion in this review, and relevant information was extracted. After scanning 1,459 documents for inclusion, our final review included 36 manuscripts and reports that included information on lung cancer service access for Indigenous peoples relative to non-Indigenous peoples. These documents included data from Aotearoa New Zealand, Australia, Canada, and the USA (including Hawai'i).
RESULTS
RESULTS
Our review found evidence of disparities in access to, and the journey through, lung cancer care for Indigenous peoples. Disparities were most obvious in access to early detection and surgery, with inconsistent evidence regarding other components of the pathway.
CONCLUSION
CONCLUSIONS
These observations are made amid relatively scant data in a global sense, highlighting the need for improved data collection and monitoring of cancer care and outcomes for Indigenous peoples worldwide. Access to early detection and guideline-concordant treatment are essential to addressing enduring disparities in cancer survival experienced by Indigenous peoples globally.
Identifiants
pubmed: 39150625
doi: 10.1007/s10552-024-01904-1
pii: 10.1007/s10552-024-01904-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Health Research Council of New Zealand
ID : 21/941
Informations de copyright
© 2024. The Author(s).
Références
Moore SP, Antoni S, Colquhoun A et al (2015) Cancer incidence in indigenous people in Australia, New Zealand, Canada, and the USA: a comparative population-based study. Lancet Oncol 16(15):1483–1492
pubmed: 26476758
doi: 10.1016/S1470-2045(15)00232-6
Condon JRBK, Barnes A, Cunningham J (2003) Cancer in Indigenous Australians: a review. Cancer Causes Control 14(2):109–121
pubmed: 12749716
doi: 10.1023/A:1023064400004
Gurney J, Robson B, Koea J, Scott N, Stanley J, Sarfati D (2020) The most commonly diagnosed and most common causes of cancer death for Maori New Zealanders. N Z Med J 133:77–96
pubmed: 32994639
Gurney J, Stanley J, McLeod M, Koea J, Jackson C, Sarfati D (2020) Disparities in cancer-specific survival between Māori and Non-Māori New Zealanders, 2007–2016. JCO Global Oncol 6:766–774
doi: 10.1200/GO.20.00028
Condon JR, Zhang X, Baade P et al (2014) Cancer survival for aboriginal and Torres Strait Islander Australians: a national study of survival rates and excess mortality. Popul Health Metrics 12(1):1
doi: 10.1186/1478-7954-12-1
Nishri ED, Sheppard AJ, Withrow DR, Marrett LD (2015) Cancer survival among first nations people of Ontario, Canada (1968–2007). Int J Cancer 136(3):639–645
pubmed: 24923728
doi: 10.1002/ijc.29024
Seffrin JR (2008) Cancer control as a human right (editorial). Lancet Oncol 9(5):409–411
pubmed: 18452851
doi: 10.1016/S1470-2045(08)70113-X
Coleman M, Forman D, Bryant H et al (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377(9760):127–138
pubmed: 21183212
pmcid: 3018568
doi: 10.1016/S0140-6736(10)62231-3
Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125):1023–1075
pubmed: 29395269
pmcid: 5879496
doi: 10.1016/S0140-6736(17)33326-3
Stevens W, Stevens G, Kolbe J, Cox B (2008) Ethnic differences in the management of lung cancer in New Zealand. J Thorac Oncol 3(3):237–244
pubmed: 18317065
doi: 10.1097/JTO.0b013e3181653d08
Fitzadam S, Lin E, Creighton N, Currow DC (2021) Lung, breast and bowel cancer treatment for Aboriginal people in New South Wales: a population-based cohort study. Intern Med J 51(6):879–890
pubmed: 32638476
pmcid: 8362177
doi: 10.1111/imj.14967
Te Aho o Te Kahu. Lung Cancer Quality Improvement Monitoring Report 2021. In: Agency CC, editor. Wellington: Cancer Control Agency; 2021.
Cassim S, Kidd J, Rolleston A et al (2021) Ha Ora: Barriers and enablers to early diagnosis of lung cancer in primary healthcare for Maori communities. Eur J Cancer Care (Engl) 30(2):e13380
pubmed: 33280179
doi: 10.1111/ecc.13380
Kidd J, Cassim S, Rolleston A et al (2021) Ha Ora: secondary care barriers and enablers to early diagnosis of lung cancer for Maori communities. BMC Cancer 21(1):121
pubmed: 33541294
pmcid: 7863263
doi: 10.1186/s12885-021-07862-0
Page BJ, Bowman RV, Yang IA, Fong KM (2016) A survey of lung cancer in rural and remote Aboriginal and Torres Strait Islander communities in Queensland: health views that impact on early diagnosis and treatment. Intern Med J 46(2):171–176
pubmed: 26550806
doi: 10.1111/imj.12948
Lawrenson R, Lao C, Brown L et al (2020) Management of patients with early stage lung cancer—why do some patients not receive treatment with curative intent? BMC Cancer 20(1):109
pubmed: 32041572
pmcid: 7011272
doi: 10.1186/s12885-020-6580-6
McKeage MJ, Tin Tin S, Khwaounjoo P et al (2020) Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand. Intern Med J 50(6):716–725
pubmed: 31318119
doi: 10.1111/imj.14435
Stevens W, Stevens G, Kolbe J, Cox B (2008) Ethnic differences in the management of lung cancer in New Zealand. J Thoracic Oncol: Off Public Int Assoc Study Lung Cancer 3(3):237–244
doi: 10.1097/JTO.0b013e3181653d08
Harrison S, Kim M (2022) Clinical quality indicators of pathways to oncological lung surgery. N Z Med J 135(1556):11–22
pubmed: 35728245
Stevens W, Stevens G, Kolbe J, Cox B (2008) Varied routes of entry into secondary care and delays in the management of lung cancer in New Zealand. Asia Pac J Clin Oncol 4(2):98–106
doi: 10.1111/j.1743-7563.2008.00158.x
Gurney J, Davies A, Stanley J et al (2024) Access to and timeliness of lung cancer surgery, radiation therapy, and systemic therapy in New Zealand: a universal health care context. JCO Global Oncol 10:e2300258
doi: 10.1200/GO.23.00258
Gurney J, Davies A, Stanley J et al (2023) Emergency presentation prior to lung cancer diagnosis: a national-level examination of disparities and survival outcomes. Lung Cancer 179:107174
pubmed: 36958240
doi: 10.1016/j.lungcan.2023.03.010
Gurney J, Davies A, Stanley J et al (2024) Equity of travel to access surgery and radiation therapy for lung cancer in New Zealand. Support Care Cancer 32:171
pubmed: 38378932
pmcid: 10879218
doi: 10.1007/s00520-024-08375-9
Gurney J, Davies A, Stanley J, et al. Equity of access to pathological diagnosis and bronchoscopy for lung cancer in Aotearoa New Zealand. New Zealand Medical Journal 2024; Under review.
Gibberd A, Supramaniam R, Dillon A, Armstrong BK, O’Connell DL (2016) Lung cancer treatment and mortality for Aboriginal people in New South Wales, Australia: results from a population-based record linkage study and medical record audit. BMC Cancer 16:289
pubmed: 27112140
pmcid: 4845365
doi: 10.1186/s12885-016-2322-1
Hall SE, Holman CD, Sheiner H (2004) The influence of socio-economic and locational disadvantage on patterns of surgical care for lung cancer in Western Australia 1982–2001. Aust Health Rev 27(2):68–79
pubmed: 15525239
doi: 10.1071/AH042720068
Hall SE, Bulsara CE, Bulsara MK et al (2004) Treatment patterns for cancer in Western Australia: does being Indigenous make a difference? Med J Aust 181(4):191–194
pubmed: 15310252
doi: 10.5694/j.1326-5377.2004.tb06234.x
Basnayake TL, Valery PC, Carson P, De Ieso PB (2021) Treatment and outcomes for indigenous and non-indigenous lung cancer patients in the Top End of the northern territory. Intern Med J 51(7):1081–1091
pubmed: 32609424
doi: 10.1111/imj.14961
Coory MD, Green AC, Stirling J, Valery PC (2008) Survival of indigenous and non-indigenous Queenslanders after a diagnosis of lung cancer: a matched cohort study. Med J Aust 188(10):562–566
pubmed: 18484926
doi: 10.5694/j.1326-5377.2008.tb01790.x
Whop LJ, Bernardes CM, Kondalsamy-Chennakesavan S et al (2017) Indigenous Australians with non-small cell lung cancer or cervical cancer receive suboptimal treatment. Asia Pac J Clin Oncol 13(5):e224–e231
pubmed: 26997361
doi: 10.1111/ajco.12463
Withrow DR, Pole JD, Nishri ED, Tjepkema M, Marrett LD (2017) Cancer survival disparities between first nation and non-aboriginal adults in Canada: follow-up of the 1991 census mortality cohort. Cancer Epidemiol Biomark Prev 26(1):145–151
doi: 10.1158/1055-9965.EPI-16-0706
McGahan CE, Linn K, Guno P et al (2017) Cancer in first nations people living in British Columbia, Canada: an analysis of incidence and survival from 1993 to 2010. Cancer Causes Control 28(10):1105–1116
pubmed: 28887646
doi: 10.1007/s10552-017-0950-7
Adams SV, Bansal A, Burnett-Hartman AN et al (2017) Cancer treatment delays in American Indians and Alaska natives enrolled in medicare. J Health Care Poor Underserv 28(1):350–361
doi: 10.1353/hpu.2017.0027
Aldrighetti CM, Niemierko A, Van Allen E, Willers H, Kamran SC (2021) Racial and ethnic disparities among participants in precision oncology clinical studies. JAMA Netw Open 4(11):e2133205
pubmed: 34748007
pmcid: 8576580
doi: 10.1001/jamanetworkopen.2021.33205
Begnaud A, Yang P, Robichaux C et al (2020) Evidence that established lung cancer mortality disparities in American Indians are not due to lung cancer genetic testing and targeted therapy disparities. Clin Lung Cancer 21(3):e164–e168
pubmed: 31759888
doi: 10.1016/j.cllc.2019.10.012
Dalwadi SM, Lewis GD, Bernicker EH, Butler EB, Teh BS, Farach AM (2019) Disparities in the treatment and outcome of stage I non-small-cell lung cancer in the 21st century. Clin Lung Cancer 20(3):194–200
pubmed: 30655194
doi: 10.1016/j.cllc.2018.11.004
Emerson MA, Banegas MP, Chawla N et al (2017) Disparities in prostate, lung, breast, and colorectal cancer survival and comorbidity status among urban American Indians and Alaskan Natives. Can Res 77(23):6770–6776
doi: 10.1158/0008-5472.CAN-17-0429
Fesinmeyer MD, Goulart B, Blough DK, Buchwald D, Ramsey SD (2010) Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whites. Cancer 116(20):4810–4816
pubmed: 20597131
doi: 10.1002/cncr.25410
Javid SH, Varghese TK, Morris AM et al (2014) Guideline-concordant cancer care and survival among American Indian/Alaskan native patients. Cancer 120(14):2183–2190
pubmed: 24711210
doi: 10.1002/cncr.28683
Narayan AK, Chowdhry DN, Fintelmann FJ, Little BP, Shepard JO, Flores EJ (2021) Racial and ethnic disparities in lung cancer screening eligibility. Radiology 301(3):712–720
pubmed: 34546133
doi: 10.1148/radiol.2021204691
Smith CB, Bonomi M, Packer S, Wisnivesky JP (2011) Disparities in lung cancer stage, treatment and survival among American Indians and Alaskan Natives. Lung Cancer 72(2):160–164
pubmed: 20889227
doi: 10.1016/j.lungcan.2010.08.015
Tantraworasin A, Taioli E, Liu B, Kaufman AJ, Flores RM (2018) Underperformance of mediastinal lymph node evaluation in resectable non-small cell lung cancer. Ann Thorac Surg 105(3):943–949
pubmed: 29397099
doi: 10.1016/j.athoracsur.2017.10.007
Hutten RJ, Weil CR, Gaffney DK et al (2022) Worsening racial disparities in utilization of intensity modulated radiation therapy. Adv Radiat Oncol 7(3):100887
pubmed: 35360509
pmcid: 8960883
doi: 10.1016/j.adro.2021.100887
Liu DM, Kwee SA (2004) Demographic, treatment, and survival patterns for native Hawaiians with lung cancer treated at a community medical center from 1995 to 2001. Pac Health Dialog 11(2):139–145
pubmed: 16281691
Oshiro CES, Frankland TB, Mor J et al (2022) Lung cancer screening by race and ethnicity in an integrated health system in Hawaii. JAMA Netw Open 5(1):e2144381
pubmed: 35050353
pmcid: 8777569
doi: 10.1001/jamanetworkopen.2021.44381
Cormack D, McLeod M (2010) Improving and maintaining quality in ethnicity data collections in the health and disability sector. Wellington
Jarrín OF, Nyandege AN, Grafova IB, Dong X, Lin H (2020) Validity of race and ethnicity codes in Medicare administrative data compared with gold-standard self-reported race collected during routine home health care visits. Med Care 58(1):e1–e8
pubmed: 31688554
pmcid: 6904433
doi: 10.1097/MLR.0000000000001216
McLeod M, Sandiford P, Kvizhinadze G, Bartholomew K, Crengle S (2020) Impact of low-dose CT screening for lung cancer on ethnic health inequities in New Zealand: a cost-effectiveness analysis. BMJ Open 10(9):e037145
pubmed: 32973060
pmcid: 7517554
doi: 10.1136/bmjopen-2020-037145
Gurney JK, Dunn A, Liu M et al (2022) The impact of COVID-19 on lung cancer detection, diagnosis and treatment for Māori in Aotearoa New Zealand. N Z Med J 135(1556):23–43
pubmed: 35728246
Sarfati D, Garvey G, Robson B et al (2018) Measuring cancer in indigenous populations. Ann Epidemiol 28(5):335–342
pubmed: 29503062
doi: 10.1016/j.annepidem.2018.02.005
McLeod M, Signal V, Gurney J, Sarfati D (2020) Postoperative mortality of indigenous populations compared with non-indigenous populations: a systematic review. JAMA Surg 155(7):636–656
pubmed: 32374369
doi: 10.1001/jamasurg.2020.0316
Parker K, Colhoun S, Bartholomew K et al (2023) Invitation methods for Indigenous New Zealand Māori in lung cancer screening: protocol for a pragmatic cluster randomized controlled trial. PLoS ONE 18(8):e0281420
pubmed: 37527237
pmcid: 10393155
doi: 10.1371/journal.pone.0281420
Te Aho o Te Kahu (2023) Cancer Control Agency. Rongohia Te Reo, Whatua He Oranga: The Voices of Whānau Māori Affected by Cancer. https://teaho.govt.nz/publications/hui-reports (Accessed 09/05/2023)
Kidd J, Cassim S, Rolleston A et al (2021) Hā Ora: secondary care barriers and enablers to early diagnosis of lung cancer for Māori communities. BMC Cancer. https://doi.org/10.1186/s12885-021-07862-0
doi: 10.1186/s12885-021-07862-0
pubmed: 34187428
pmcid: 8243723
Rankin A, Baumann A, Downey B, Valaitis R, Montour A, Mandy P (2022) The role of the indigenous patient navigator: a scoping review. Can J Nurs Res 54(2):199–210
pubmed: 35014886
pmcid: 9109580
doi: 10.1177/08445621211066765
Te Aho O Te Kahu (2022) Cancer Control Agency. He Mahere Ratonga Mate Pukupuku - Cancer Service Planning: A vision for cancer treatment in the reformed health system. Wellington, New Zealand: Te Aho o Te Kahu - Cancer Control Agency